Center for Scientific Review; Notice of Closed Meetings, 57383-57384 [2015-24133]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 184 / Wednesday, September 23, 2015 / Notices
solution to this delivery problem, RNAi
cannot fulfill its therapeutic promise.
Investigators at the National Institutes
of Health have developed novel
compositions and methods for
delivering inhibitory oligonucleotides to
cells in a targeted and efficient manner.
The compositions and methods are
based on utilizing a cell surface receptor
targeting ligand, such as cytokine or
chemokine, and a domain that binds an
inhibitory oligonucleotide, to efficiently
deliver the inhibitory oligonucleotide to
the cell that expresses the cell surface
receptor targeting ligand. Chemokine
receptors are differentially expressed on
various cells, including tumors; hence
this technology allows targeting siRNA
to aberrant cells. Gene silencing can also
be achieved in variety of immune cells
by targeting cytokine receptors. This
technology has great potential for
developing into a safe and effective
means of delivering therapeutic siRNAs.
Potential Commercial Applications
• Treatment of cancers and
autoimmune diseases by delivery of
siRNA to tumor cells or various
aberrantly functioning immune cells.
• This technology can be used to
boost vaccine responses against cancers
and chronic infectious diseases.
• Targeted delivery of fluorochromelabeled RNA both in vitro and in vivo for
diagnostic purposes, for example, to
trace or localize various cells and to
determine tumor metastasis and
aberrant proliferation or homing of
immune cells.
mstockstill on DSK4VPTVN1PROD with NOTICES
Competitive Advantages
• Simple method for linking siRNA to
polypeptides to create non-covalent or
covalent complexes
• In vivo targeted delivery of
inhibitory RNAs into cells rather than
systemically
• Delivery of multiple inhibitory
RNAs to target multiple genes
• Long-term repression of target gene
expression through RNAi phenomenon
Development Stage
• In vitro data available
• In vivo data available (animal)
• In situ data available
Inventors: Bira Arya, Purevdorj
Olkhanud, Juan Espinoza (all of NIA)
Intellectual Property: HHS Reference
No. E–051–2008/0—
• US Patent No. 8,703,921 issued 22
Apr 2014
• US Patent Application No. 14/
220,726 filed 20 Mar 2014
• Various international patents/patent
applications
Licensing Contact: Betty B. Tong,
Ph.D.; 301–594–6565; tongb@
mail.nih.gov
VerDate Sep<11>2014
18:00 Sep 22, 2015
Jkt 235001
Collaborative Research Opportunity:
The National Institute on Aging,
Laboratory of Molecular Biology and
Immunology, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize chemokine-based siRNA/
shRNA technology for treatment of
cancers and autoimmune diseases, i.e.
to control expression of
immunomodulatory cytokines and other
factors that facilitate tumor escape,
activity of regulatory T cells or Th2 type
of cells. This technology can be also
utilized to boost vaccine responses
against cancers and chronic infectious
diseases. Please contact John D. Hewes,
Ph.D. at 240–276–5515 or john.hewes@
nih.gov for more information.
Dated: September 17, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–24137 Filed 9–22–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Bioengineering Sciences
Biocomputational and Modeling.
Date: October 28, 2015.
Time: 2:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Joseph Thomas Peterson,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4118,
MSC 7814, Bethesda, MD 20892, 301–408–
9694, petersonjt@csr.nih.gov.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
57383
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Cell Biology, Developmental
Biology, and Bioengineering.
Date: October 29–30, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Raj K. Krishnaraju, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6190,
Bethesda, MD 20892, 301–435–1047,
kkrishna@csr.nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group; Cellular and Molecular
Biology of Glia Study Section.
Date: October 29–30, 2015.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton McLean Tysons Corner, 7920
Jones Branch Drive, McLean, VA 22102.
Contact Person: Linda MacArthur, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4187,
Bethesda, MD 20892, 301–537–9986,
macarthurlh@csr.nih.gov.
Name of Committee: Oncology 1-Basic
Translational Integrated Review Group;
Tumor Progression and Metastasis Study
Section.
Date: October 29–30, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites, DC Convention
Center, 900 10 Street, Washington, DC 20001.
Contact Person: Rolf Jakobi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6187,
MSC 7806, Bethesda, MD 20892, 301–495–
1718, jakobir@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Bacterial Pathogenesis.
Date: October 29–30, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Warwick Allerton Hotel, 701
North Michigan Avenue, Chicago, IL 60611.
Contact Person: Richard G. Kostriken,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3192,
MSC 7808, Bethesda, MD 20892, 240–519–
7808, kostrikr@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Biophysical, Physiological,
Pharmacological and Bioengineering
Neuroscience.
Date: October 29–30, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Westin Georgetown, 2350 M St.
NW., Washington, DC 20037.
E:\FR\FM\23SEN1.SGM
23SEN1
57384
Federal Register / Vol. 80, No. 184 / Wednesday, September 23, 2015 / Notices
Contact Person: Paula Elyse Schauwecker,
Ph.D., Scientific Review Officer, National
Institutes of Health, Center for Scientific
Review, 6701 Rockledge Drive, Room 5211,
Bethesda, MD 20892, schauweckerpe@
csr.nih.gov.
Name of Committee: Cell Biology
Integrated Review Group; Cellular
Mechanisms in Aging and Development
Study Section.
Date: October 29–30, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: John Burch, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 3213,
MSC 7808, Bethesda, MD 20892, 301–408–
9519, burchjb@csr.nih.gov.
Name of Committee: Genes, Genomes, and
Genetics Integrated Review Group; Genetics
of Health and Disease Study Section.
Date: October 29–30, 2015.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Contact Person: The Fairmont Washington,
DC, 2401 M Street NW., Washington, DC
20037.
Contact Person: Cheryl M. Corsaro, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2204,
MSC 7890, Bethesda, MD 20892, (301) 435–
1045, corsaroc@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 18, 2015.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–24133 Filed 9–22–15; 08:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF THE INTERIOR
[FWS–R4–FHC–2015–N160;
FVHC98210408710–XXX–FF04G01000]
Deepwater Horizon Oil Spill; Final
Phase IV Early Restoration Plan and
Environmental Assessments
Interior.
Notice of availability.
AGENCY:
ACTION:
In accordance with the Oil
Pollution Act of 1990 (OPA), the
National Environmental Policy Act
(NEPA), and the Framework Agreement
for Early Restoration Addressing
Injuries Resulting from the Deepwater
Horizon Oil Spill, notice is hereby given
that the Federal and State natural
resource trustee agencies (Trustees)
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:00 Sep 22, 2015
Jkt 235001
have approved the Phase IV Early
Restoration Plan and Environmental
Assessments (Phase IV ERP/EAs). The
Trustees have selected 10 early
restoration projects in the Phase IV ERP/
EAs that are consistent with the early
restoration program alternatives selected
in the final Phase III Early Restoration
Plan/Programmatic Environmental
Impact Statement (Phase III ERP/PEIS).
The projects selected in the Phase IV
ERP/EAs will continue the process of
restoring natural resources and services
injured or lost as a result of the
Deepwater Horizon oil spill, which
occurred on or about April 20, 2010, in
the Gulf of Mexico. The Phase IV ERP/
EAs also retains a notice of change and
supporting analysis for one Phase III
Early Restoration Project,
‘‘Enhancement of Franklin County Parks
and Boat Ramps—Eastpoint Fishing Pier
Improvements’’ that was included in the
Draft Phase IV plan.
ADDRESSES: Obtaining Documents: You
may download the Phase IV ERP/EAs at:
https://www.gulfspillrestoration.noaa.gov
or https://www.doi.gov/
deepwaterhorizon. Alternatively, you
may request a CD of the Phase IV ERP/
EAs (see FOR FURTHER INFORMATION
CONTACT). You may also view the
document at any of the public facilities
listed at https://
www.gulfspillrestoration.noaa.gov.
FOR FURTHER INFORMATION CONTACT:
Nanciann Regalado, at nanciann_
regalado@fws.gov.
SUPPLEMENTARY INFORMATION:
Introduction
On or about April 20, 2010, the
mobile offshore drilling unit Deepwater
Horizon, which was being used to drill
a well for BP Exploration and
Production, Inc. (BP), in the Macondo
prospect (Mississippi Canyon 252–
MC252), experienced a significant
explosion, fire, and subsequent sinking
in the Gulf of Mexico, resulting in an
unprecedented volume of oil and other
discharges from the rig and from the
wellhead on the seabed. The Deepwater
Horizon oil spill is the largest oil spill
in U.S. history, discharging millions of
barrels of oil over a period of 87 days.
In addition, well over 1 million gallons
of dispersants were applied to the
waters of the spill area in an attempt to
disperse the spilled oil. An
undetermined amount of natural gas
was also released into the environment
as a result of the spill.
The Trustees are conducting the
natural resource damage assessment for
the Deepwater Horizon oil spill under
the Oil Pollution Act 1990 (OPA; 33
U.S.C. 2701 et seq.). Pursuant to OPA,
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Federal and State agencies act as
trustees on behalf of the public to assess
natural resource injuries and losses, and
to determine the actions required to
compensate the public for those injuries
and losses. OPA further instructs the
designated trustees to develop and
implement a plan for the restoration,
rehabilitation, replacement, or
acquisition of the equivalent of the
injured natural resources under their
trusteeship, including the loss of use
and services from those resources from
the time of injury until the time of
restoration to baseline (the resource
quality and conditions that would exist
if the spill had not occurred) is
complete. Pursuant to the process
articulated in the Framework for Early
Restoration Addressing Injuries
Resulting from the Deepwater Horizon
Oil Spill (Framework Agreement), the
Trustees previously selected, and BP
agreed to fund, a total of 54 early
restoration projects, expected to cost
approximately $700 million, through
the Phase I Early Restoration Plan/
Environmental Assessment (Phase I
ERP/EA), Phase II Early Restoration
Plan/Environmental Review (Phase II
ERP/ER), and the Programmatic and
Phase III Early Restoration Plan and
Early Restoration Programmatic
Environmental Impact Statement (Phase
III ERP/PEIS). These plans are available
at: https://
www.gulfspillrestoration.noaa.gov/
restoration/early-restoration/
The Trustees are:
• U.S. Department of the Interior
(DOI), as represented by the National
Park Service, U.S. Fish and Wildlife
Service, and Bureau of Land
Management;
• National Oceanic and Atmospheric
Administration (NOAA), on behalf of
the U.S. Department of Commerce;
• U.S. Department of Agriculture
(USDA);
• U.S. Department of Defense
(DOD); 1
• U.S. Environmental Protection
Agency (USEPA);
• State of Louisiana Coastal
Protection and Restoration Authority,
Oil Spill Coordinator’s Office,
Department of Environmental Quality,
Department of Wildlife and Fisheries,
and Department of Natural Resources;
• State of Mississippi Department of
Environmental Quality;
• State of Alabama Department of
Conservation and Natural Resources and
Geological Survey of Alabama;
1 Although a trustee under OPA by virtue of the
proximity of its facilities to the Deepwater Horizon
oil spill, DOD is not a member of the Trustee
Council and does not currently participate in
Trustee decision making.
E:\FR\FM\23SEN1.SGM
23SEN1
]]>Agencies
[Federal Register Volume 80, Number 184 (Wednesday, September 23, 2015)]
[Notices]
[Pages 57383-57384]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24133]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Bioengineering Sciences Biocomputational and
Modeling.
Date: October 28, 2015.
Time: 2:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Joseph Thomas Peterson, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4118, MSC 7814, Bethesda, MD
20892, 301-408-9694, petersonjt@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Fellowships: Cell Biology, Developmental Biology, and
Bioengineering.
Date: October 29-30, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Raj K. Krishnaraju, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6190, Bethesda, MD 20892, 301-
435-1047, kkrishna@csr.nih.gov.
Name of Committee: Molecular, Cellular and Developmental
Neuroscience Integrated Review Group; Cellular and Molecular Biology
of Glia Study Section.
Date: October 29-30, 2015.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton McLean Tysons Corner, 7920 Jones Branch Drive,
McLean, VA 22102.
Contact Person: Linda MacArthur, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4187, Bethesda, MD 20892, 301-
537-9986, macarthurlh@csr.nih.gov.
Name of Committee: Oncology 1-Basic Translational Integrated
Review Group; Tumor Progression and Metastasis Study Section.
Date: October 29-30, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites, DC Convention Center, 900 10 Street,
Washington, DC 20001.
Contact Person: Rolf Jakobi, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 6187, MSC 7806, Bethesda, MD 20892, 301-495-
1718, jakobir@mail.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Topics in Bacterial Pathogenesis.
Date: October 29-30, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: The Warwick Allerton Hotel, 701 North Michigan Avenue,
Chicago, IL 60611.
Contact Person: Richard G. Kostriken, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3192, MSC 7808, Bethesda, MD
20892, 240-519-7808, kostrikr@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Fellowships: Biophysical, Physiological, Pharmacological and
Bioengineering Neuroscience.
Date: October 29-30, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: The Westin Georgetown, 2350 M St. NW., Washington, DC
20037.
[[Page 57384]]
Contact Person: Paula Elyse Schauwecker, Ph.D., Scientific
Review Officer, National Institutes of Health, Center for Scientific
Review, 6701 Rockledge Drive, Room 5211, Bethesda, MD 20892,
schauweckerpe@csr.nih.gov.
Name of Committee: Cell Biology Integrated Review Group;
Cellular Mechanisms in Aging and Development Study Section.
Date: October 29-30, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda,
MD 20814.
Contact Person: John Burch, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institute of Health, 6701
Rockledge Drive, Room 3213, MSC 7808, Bethesda, MD 20892, 301-408-
9519, burchjb@csr.nih.gov.
Name of Committee: Genes, Genomes, and Genetics Integrated
Review Group; Genetics of Health and Disease Study Section.
Date: October 29-30, 2015.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Contact Person: The Fairmont Washington, DC, 2401 M Street NW.,
Washington, DC 20037.
Contact Person: Cheryl M. Corsaro, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2204, MSC 7890, Bethesda, MD
20892, (301) 435-1045, corsaroc@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: September 18, 2015.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-24133 Filed 9-22-15; 08:45 am]
BILLING CODE 4140-01-P
